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CA125 is a glycoprotein (200 KD) expressed by epithelial
ovarian tumors. CA125 levels in serum can be used to
follow response to treatment in patients with ovarian
carcinoma. However, elevated CA125 serum levels have
also been reported in other gynecological pathologies,
some non-gynecological malignant disorders and even in
benign pleural or abdominal effusions (1, 2).
Since 1995, several papers reported the association of
high CA125 serum levels with non-Hodgkin’s lymphoma
(NHL). With the exception of age, most of the IPI’s (3)
factors were found to be associated with high CA125 levels
in six prospective or retrospective studies (1, 2, 4–7). Bulky
disease and/or high tumor burden were reported to be
associated with high CA125 levels in seven studies (1, 2, 4,
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5, 7–9). Produced by mesothelial cells, this biological mar-
ker appeared to be strongly correlated with the presence of
effusions and abdominal involvement. The association
with B symptoms or bone marrow involvement has also
been described in some studies (1, 4, 6, 7, 9, 10). Finally,
CA125 serum level at diagnosis has been reported to be a
new prognostic factor (1, 4, 6, 7) and it has been proposed
to incorporate it in the current prognostic index. On the
other hand, CA125 levels have rarely been examined in
patients with Hodgkin’s disease (HD).
In this study, we analyzed the clinical characteristics
associated with elevated CA125 levels at diagnosis and
examined whether abnormal CA125 serum levels were
associated with altered overall survival (OS) or progres-
sive-free survival (PFS) in 99 patients with HD or NHL.
Patients and methods
Patients
Between July 2000 and January 2005, 99 consecutive
patients hospitalized in our center with newly diagnosed
NHL or HD underwent serum CA125 assessment at
diagnosis. Their characteristics are detailed in Table 1.
Tumors were classiﬁed according to the REAL classiﬁca-
tion (11). The extent of the disease was evaluated by
means of physical examination, computed tomography
of the chest, abdomen and pelvis, total body PET scan-
ner, bone marrow biopsy, as well as other investigations
depending on clinical symptoms and signs. Staging was
deﬁned on the basis of the Ann Arbor classiﬁcation (12).
Performance status was assessed according to the Eastern
Cooperative Oncology Group scale.
Laboratory analyses
All laboratory analyses were determined on fresh samples
collected on the same day at diagnosis. Serum CA125 was
measured on a Modular E170 autoanalyser by Electro-
chemiluminescence Immunoassay (Roche, Basel, Switzer-
land) with a measuring range of 0.6–5000 UI/mL
(reference range 0–35 UI/mL). Serum b2-microglobulin
(Radioimmunoassay; Immunotech, Prague, Czech Repub-
lic, reference range 1–2.5 mg/L), serum lactate deshydrog-
enase (LDH) (enzymatic UV-assay; Roche, reference
range 240–480 UI/L), hemoglobin (Cyanmethemoglobin
method; Bayer Technicon, Tarrytown, NY, USA) and C-
reactive protein (CRP) (Immunoturbidimetric assay;
Roche) were also obtained in all patients.
Statistical analyses
Results were expressed as means ± standard deviations,
medians and ranges for continuous variables and as
percentages for categorical variables. Biological parame-
ters were log-transformed whenever appropriate. Patients
with normal or elevated CA125 levels were compared by
logistic regression for each variable separately but also
for all variables combined into a backward selection pro-
cedure (13). OS and PFS were evaluated by Cox regres-
sion models with application of a backward selection
procedure. Multivariate analyses were carried out by
adjusting for the histological group and in the case of
OS and PFS for CA125 levels. Results were considered
to be signiﬁcant at the 5% level (P < 0.05). Data analy-
sis was carried out using SAS 9.1 for Windows (SAS
Institute, Cary, NC, USA) statistical package.
Results
Characteristics of the patients (demography, clinical and
biological parameters) are listed in Table 1 for the total
population and within each histological group. There were
27 patients with indolent NHL (Lymphocytic lymphoma
n ¼ 1, follicular lymphoma n ¼ 15, malt lymphoma n ¼
6, unclassiﬁed n ¼ 5), 51 with aggressive NHL (Diffuse
large B cell lymphoma n ¼ 39, mantle cell lymphoma n ¼
6, anaplastic large cell lymphoma n ¼ 2, periperal T-cell
lymphoma n ¼ 3, Burkitt’s lymphoma n ¼ 1) and 21
patients with HD (Nodular lymphocyte-predominant HD
n ¼ 3, nodular sclerosis HD n ¼ 16, mixed cellularity HD
n ¼ 1, unclassiﬁed HD n ¼ 1). There were 42 (42%)
women and 57 (58%) men, mean age was 57 ± 18 yr
(median 58 yr, range 15–88 yr). Among patients, 17% had
poor performance status, 22% presented B symptoms,
58% had an advanced clinical stage, 50% abdominal,
40% mediastinal and 28% bone marrow involvement, and
14% an effusion. The aaIPI was ‡1 in 37% of the patients.
CA125 serum level was 105 ± 368 UI/mL and was
elevated in 34 patients (34%). Proportions of patients
with elevated CA125 serum levels did not signiﬁcantly
differ among the three histological groups (indolent
NHL: 19%, aggressive NHL: 45%, HD: 29%; P ¼
0.059). There was also no signiﬁcant difference for age
(P ¼ 0.46) and sex (P ¼ 0.86). Patients with elevated
CA125 serum levels had more frequently poor perform-
ance status (37% vs. 8%, P ¼ 0.0015), B symptoms
(42% vs. 11%, P ¼ 0.0009), advanced clinical stage
(88% vs. 42%, P < 0.0001), abdominal (74% vs. 37%,
P ¼ 0.0008), mediastinal (62% vs. 29%, P ¼ 0.002) or
bone marrow (47% vs. 19%, P ¼ 0.004) involvement
and presence of effusions (36% vs. 2%, P ¼ 0.0009).
They had also higher aaIPI (75% vs. 17%, P < 0.0001).
Finally, they exhibited lower Hb levels (12 ± 2.4 vs.
14 ± 1.9 g/dL, P ¼ 0.002), higher CRP (58 ± 83 vs.
21 ± 33 mg/L, P ¼ 0.0003), LDH (900 ± 883 vs. 500 ±
530 UI/L, P < 0.0001) and b2-microglobulin (4.1 ± 2.7
vs. 2.2 ± 1.3 mg/L, P < 0.0001) levels.
CA125 measurement in lymphoma Bonnet et al.
400
ª 2007 The Authors
Journal compilation 78 (399–404) ª 2007 Blackwell Munksgaard
When the analysis was restricted to patients with
indolent lymphomas, those with elevated CA125 serum
levels had more often mediastinal involvement (60% vs.
14%, P ¼ 0.042), higher aaIPI (60% vs. 10%, P ¼
0.024), higher LDH (564 ± 186 vs. 348 ± 82 UI/L,
P ¼ 0.022), CRP (25 ± 23 vs. 7 ± 10 mg/L, P ¼
0.049) and b2-microglobulin (5.0 ± 2.8 vs.
2.1 ± 0.8 mg/L, P ¼ 0.024) levels.
In aggressive NHL, patients with elevated CA125 serum
levels had more frequently poor performance status (40%
vs. 11%, P ¼ 0.028), B symptoms (41% vs. 4%, P ¼
0.0091), advanced clinical stage (96% vs. 46%, P ¼
0.003), abdominal (78% vs. 32%, P ¼ 0.0017), mediasti-
nal (52% vs. 18%, P ¼ 0.013) or bone marrow (44% vs.
11%, P ¼ 0.012) involvement, high aaIPI (81% vs. 30%,
P ¼ 0.0009), low Hb (12 ± 2.5 vs. 14 ± 1.7 g/dL, P ¼
0.027), high CRP (63 ± 91 vs. 24 ± 34 mg/L, P ¼
0.043), LDH (1051 ± 1045 vs. 677 ± 778 UI/L, P ¼
0.0081) or b2-microglobulin (4.3 ± 2.9 vs. 2.5 ± 1.7 mg/
L, P ¼ 0.0057) levels.





















Female 44 35 57 42
Male 56 65 43 58
Clinical parameters
Performance status
0–1 92 77 85 82
‡2 8 23 15 17
B symptoms
No 85 80 67 78
Yes 15 20 33 22
Ann Arbor stage
I 37 16 14 21
II 3.7 16 57 21
III 3.7 18 9.5 12
IV 56 51 19 46
Sites of tumor
Abdominal 63 53 24 50
Mediastinal 22 33 81 40
Bone Marrow 44 26 14 28
Effusion 13 16 9.5 14
aaIPI
0 35 21 48 31
1 46 27 29 33
2 15 31 24 25
3 3.9 21 0 12
Biological parameters








% elevated (‡35 UI/mL) 19 45 29 34
































Hb, hemoglobin; CRP, C-reactive protein; LDH, lactate deshydrogenase.
* For continuous variables: mean ± SD (median, range) and for categorical variables: %.
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In multivariate analysis adjusted for histological group,
only bone marrow involvement (P ¼ 0.032), the presence
of effusion (P ¼ 0.009) and high aaIPI (P ¼ 0.002) were
signiﬁcantly associated with high CA125 serum levels.
OS was signiﬁcantly worse for patients with poor per-
formance status hazard ratio (HR ¼ 5.1, P < 0.0005), B
symptoms (HR ¼ 4.3, P ¼ 0.0014), advanced clinical
stage (HR ¼ 3.3, P ¼ 0.033), bone marrow involvement
(HR ¼ 2.8, P ¼ 0.02), high aaIPI (HR ¼ 5.3, P ¼
0.0006), low Hb (HR ¼ 0.03, P ¼ 0.001), high CRP
(HR ¼ 1.5, P ¼ 0.007) and high b2-microglobulin
(HR ¼ 5.9, P < 0.0001) (Table 2, Fig. 1). Progression-
free survival (PFS) was signiﬁcantly worse for older
patients (HR ¼ 1.03, P ¼ 0.004), those with poor per-
formance status (HR ¼ 3.0, P ¼ 0.007), B symptoms
(HR ¼ 2.3, P ¼ 0.031), advanced clinical stage (HR ¼
4.6, P ¼ 0.0019), abdominal (HR ¼ 2.8, P ¼ 0.009) as
well as bone marrow (HR ¼ 2.9, P ¼ 0.003) involve-
ment, high aaIPI (HR ¼ 3.9, P ¼ 0.0004), low Hb
(HR ¼ 0.15, P ¼ 0.035), high CRP (HR ¼ 1.3, P ¼
0.036) and high b2-microglobulin (HR ¼ 4.1,
P < 0.0001) (Table 2). OS and PFS were not different in
patients with normal or elevated CA125 levels.
In multivariate Cox models, when adjusting for
CA125 levels and for histological group, OS and PFS
were signiﬁcantly affected adversely only by high b2-
microglobulin (OS: HR ¼ 7.1, P < 0.0001; PFS: HR ¼
5.9, P < 0.0001) (Table 3). For PFS, we also noted a
worse outcome for men (HR ¼ 2.7, P ¼ 0.015). There
was no effect of CA125 levels (OS, P ¼ 0.18; PFS, P ¼
0.48) and no difference between histological groups (OS:
P > 0.5; PFS: P > 0.5).
Discussion
In this study, we retrospectively evaluated the signiﬁ-
cance of CA125 serum levels in 99 patients with lym-
phoma. We ﬁrst analyzed the clinical and biological
characteristics associated with elevated CA125 levels at
diagnosis. High CA125 serum levels were observed in
34% of the patients. This percentage is comparable with
ﬁgures previously reported by other authors (2, 5–7, 14–
17). In univariate analysis, many characteristics of more
advanced disease were associated with elevated CA125
values. However, in multivariate analysis, an association
was only found between high CA125 serum levels, on the
one hand, and the presence of effusions, marrow involve-
ment and high aaIPI, on the other. These results have
been previously found by others (1, 2, 4–10, 17).
It is now proven that it is not the malignant lympho-
cytes but mesothelial cells that produce CA125 (1, 4, 5,
10, 14). Inﬂammatory cytokines, such as IL-1 and TNF-
a, produced by macrophages and lymphoma cells, are





Hazard ratio P-value Hazard ratio P-value
Histology
Lymphoma1
Indolent 0.71 0.67 2.5 0.16
Aggressive 2.26 0.20 2.7 0.11
Demography
Age (years) 1.02 0.08 1.03 0.004
Sex
Male 1.09 0.85 1.6 0.19
Clinical parameters
Performance status
2–3 5.1 0.0005 3.0 0.007
B symptoms
Yes 4.3 0.0014 2.3 0.031
Ann Arbor stage
III–IV 3.3 0.033 4.6 0.0019
Sites of tumor
Abdominal 1.7 0.23 2.8 0.0088
Mediastinal 2.3 0.06 1.1 0.71
Bone marrow 2.8 0.02 2.9 0.003
Effusion 1.2 0.81 1.9 0.18
AaIPI
2–3 5.3 0.0006 3.9 0.0004
Biological parameters
CA125
‡ 35 UI/mL 1.8 0.20 1.8 0.11
Hb (g/dL)2 0.03 0.001 0.15 0.035
CRP (mg/L)2 1.5 0.007 1.3 0.036
LDH (UI/L) 2 1.8 0.06 1.6 0.057
b2)microglobulin (mg/L) 2 5.9 <0.0001 4.1 <0.0001
Hb, hemoglobin; CRP, C-reactive protein; LDH, lactate deshydroge-
nase.
1 Reference ¼ Hodgkin’s disease.
2 Log-transformation.




























Figure 1 Overall Survival according to b2-microglobulin level at
diagnosis.
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suspected to stimulate CA125 (1, 4, 14), but also IL-6
and IL-8 production (5, 15). The presence of effusion or
the involvement of serous membranes (such as the peri-
toneum, pericardium or pleura) can thus enhance CA125
production by mesothelial cells (1, 2). Because of CA125
production by cells other than lymphoma cells, its serum
levels are more a reﬂection of the inﬂammatory response
to the disease than of the tumor mass itself. As cytokine
production is proportional to the tumor mass (15), it is
not surprising that CA125 are mostly found in associ-
ation with various characteristics of advanced disease.
We now have good prognostic factors, such as the aaI-
PI (3) for aggressive NHL and the FLIPI (18) for follicu-
lar lymphoma. Given the association of CA125 levels
with higher aaIPI, the gold standard of prognostic evalu-
ation of lymphoma patients, one could predict that
CA125 levels would not enhance that prognostic assess-
ment. Indeed, CA125 serum levels did not improve its
performance in our study. It would therefore be inappro-
priate to take therapeutic decisions based on CA125
serum levels.
Some authors have reported worse outcome in patients
with high CA125 levels (1, 4, 7, 8). In univariate analysis,
Bairey et al. (4) found signiﬁcantly worse OS in patients
with aggressive NHL and elevated CA125 but this biolo-
gical factor lost its prognostic signiﬁcance in multivariate
analysis. Zacharos et al. (1) observed 5-yr survival of
65% vs. 20% in patients with aggressive NHL and nor-
mal or elevated CA125, respectively. This difference
remained signiﬁcant in multivariate analysis. Benboubker
et al. (7) reported signiﬁcantly better outcome in patients
with low-grade NHL and normal CA125 levels but the
results of multivariate analyses are unknown. Finally, in
a study of 38 patients, Zidan et al. (6) showed inferior
OS for patients with aggressive NHL and high CA125
levels (5-yr OS: 35% vs. 76%, respectively). This differ-
ence remained signiﬁcant after the population was split
into histological subgroups. We were not able to conﬁrm
this. In our series, only b2-microglobulin worsened PFS
or OS. This result has already been reported and is now
well validated (15). These contradictory results could be
related to different patient populations and treatments,
and should be better investigated in multicenter studies
including more patients, receiving the same treatment
and presenting homogenous histological and clinical fea-
tures.
The role of CA125 levels in the early detection of
relapse in CA125-producing patients has also been repor-
ted (1, 2, 4, 6). Perhaps, other methods, such as PET
scans or combined CT-PET scans (19), would be more
efﬁcient, though more costly but this remains to be
prove. However, the decrease of CA125 serum levels dur-
ing therapy could be an argument for adequate tumor
response to therapy in so far as there are no concomitant
abdominal, pericardial or pleural abnormalities.
In conclusion, while CA125 serum level correlates
with a number of features associated with more aggres-
sive disease, it does not enhance the performance of
standard prognostic factors in the treatment of patients
with NHL or HD.
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